Notícias Corporativas

Qarziba® is an anti-GD2 monoclonal antibody that has shown to improve significantly the event-free and overall survival in children with high-risk neuroblastoma, with an acceptable safety profile.

FarmaMondo and Accendatech USA Inc. partnered to initiate a Managed Access Program for the compassionate supply of ACT-001 for patients in Hong Kong. Under the

September 17, 2021 – Oasmia Pharmaceutical AB, an oncology-focused specialty pharmaceutical company, today announces that it has signed a license agreement with the Swiss-based FarmaMondo

Mirum Pharmaceuticals (NASDAQ: MIRM) and FarmaMondo entered into an exclusive distribution and supply agreement appointing the FarmaMondo Group as the exclusive partner to make their

Ideogen AG and FarmaMondo enter into an exclusive Managed Access Program distribution agreement appointing the FarmaMondo Group as the exclusive partner for their innovative PTCL

The FarmaMondo Group announces the establishment of FarmaMondo Pte, a fully owned subsidiary in Singapore. FarmaMondo Pte Singapore will further serve the Group’s development strategy

February 2021 FarmaMondo SA announces the establishment of FarmaMondo Iberia, in Portugal, a fully owned subsidiary of FarmaMondo SA. The Iberian Subsidiary will further enhance